Role of Serum Levels of Thymidine Kinase 1 in Diagnosis and Differentiating of Prostatic Tumor
Keywords:Serum, Thymidine Kinase 1, prostatic tumor
Background: Both benign prostatic (BPH) and prostate (Pca) hyperplasia include prostate enlargement. The
distinction between benign prostatic hyperplasia and prostate cancer is a major challenge, since the prostatic
specific antigen (PSA) cannot be considered a reliable predictor of prostate cancer. Aims: Efficiency of
serum thymidine kinase 1 and PSA-related biomarkers in prostate tumor, BPH and PCa diagnosis and
differentiation, especially when serum PSA is in the gray (4-10 ng/ml) region and in the pronostic of these
patients after surgical therapy. Subjects and Methods: A case control and cross-sectional review. There
were 110 elderly patients (45-81 years) and 45 controle. Serum experiments involved the use of ELISA
technologies to measure tPSA, fPSA, and TK1. Result: In comparison to both of the BPH and controls, the
mean (±S D) of serum tPSA and fPSA in Pca were significantly improved (all p =0,001) while the mean
value of f PCa in comparison with BPH and control was dramatically decreased (p = 0,001) for fPSA/tPSA.
There was no difference between BPH and controls in these parameters. In both of the Pca and Controls
(P<0.001) the mean TC1 was slightly higher (P<0.001). This serum TK1 has the most receptive and specific
diagnostic and differentiating potency in the gray zone of tPSA (4-10 ng/ml), which has tPSA in the gray
zone with AUC=1 in the 924 pg/ml cut-off zone.
Conclusion: Serum level of TK1 was superior of tPSA in diagnosis of prostate tumor and differentiating
between BPH and PCa.
How to Cite
- The journal allows readers to read, download, copy, distribute, print, search, or link to the full texts of its articles and allow readers to use them for any other lawful purpose.
- The journal allows the author(s) to hold the copyright without restrictions.
- The journal allows the author(s) to retain publishing rights without restrictions